Details of the Drug Reposition

General Information of This Drug (ID: DMOG2X1)

Drug Name
Trebananib   DMOG2X1
Drug Type
Recombinant protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Renal cell carcinoma DISQZ2X8 2C90 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health.